The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 11, 2022

Filed:

Jul. 17, 2019
Applicants:

Technische Universität München, Munich, DE;

Biotechnologicky Ustav Av Cr, V.v.i., Vestec, CZ;

Inventors:

Arne Skerra, Freising, DE;

Antonia Richter, Freising, DE;

Volker Morath, Freising, DE;

Cyril Barinka, Prague, CZ;

Jakub Ptacek, Prague, CZ;

Assignee:

Other;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/17 (2006.01); A61K 49/00 (2006.01); C07K 14/47 (2006.01); C07K 7/06 (2006.01); C07K 7/08 (2006.01); C07K 14/705 (2006.01); C07K 19/00 (2006.01); C12N 15/62 (2006.01); G01N 33/533 (2006.01); G01N 33/574 (2006.01);
U.S. Cl.
CPC ...
A61K 49/0017 (2013.01); A61K 38/177 (2013.01); C07K 7/06 (2013.01); C07K 7/08 (2013.01); C07K 14/4721 (2013.01); C07K 14/4748 (2013.01); C07K 14/705 (2013.01); C07K 19/00 (2013.01); C12N 15/62 (2013.01); G01N 33/533 (2013.01); G01N 33/57434 (2013.01); C07K 2318/20 (2013.01); C07K 2319/036 (2013.01); C07K 2319/10 (2013.01); C07K 2319/33 (2013.01); C07K 2319/61 (2013.01); C07K 2319/74 (2013.01);
Abstract

The present invention relates to a prostate-specific membrane antigen (PSMA)-specific binding protein, wherein the PSMA-specific binding protein is a lipocalin 2 (Lcn2)-derived binding protein and binds to PSMA with a Kof 10 nM or lower. The present invention also relates to a nucleic acid molecule encoding the PSMA-specific binding protein of the invention, a vector comprising said nucleic acid molecule of the invention and a host cell transformed with the vector. Furthermore, the invention relates to a method of producing the PSMA-specific binding protein of the invention, the method comprising culturing the host cell of the invention under suitable conditions and isolating the PSMA-specific binding protein produced. The present invention further relates to a protein conjugate comprising the PSMA-specific binding protein of the invention, or the PSMA-specific binding protein produced by the method of the invention. In addition, the present invention relates to a pharmaceutical or diagnostic composition; to the PSMA-specific binding protein of the invention, the nucleic acid molecule of the invention, the vector of the invention, the host cell of the invention or the PSMA-specific binding protein produced by the method of the invention, for use in therapy and/or diagnosis, and in particular for use in the therapy and/or diagnosis of tumors, Crohn's disease and/or neurological diseases.


Find Patent Forward Citations

Loading…